Conference Reports for NATAP

Back

Tweet

19th International Workshop on Clinical Pharmacology of Antiviral Therapy May 22, 2018 Baltimore, USA | Baltimore Marriott Inner Harbor     Population pharmacokinetic analysis for darunavir and tenofovir alafenamide in HIV-1-infected patients on the darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (AMBER and EMERALD studies) - (06/4/18)   SIMULATED PHARMACOKINETIC INTERACTIONS OF RIFAMPICIN WITH RITONAVIR-BOOSTED DARUNAVIR - (06/4/18)   Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202 - (06/4/18)   Defining total-body AIDS-virus burden with implications for curative strategies - (05/31/18)   Age, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals' Concentrations - (05/31/18)   Differential brain tissue penetration of antiretrovirals and fluconazole - (05/30/18)   Effects of Low and High Mineral Water Content on the Relative Bioavailability of a Co-Formulated TRIUMEQ (Abacavir/Dolutegravir/Lamivudine) Dispersible Tablet in Healthy Adults - (05/28/18)   More than half of 75-and-older Swiss HIV group takes 5 or more non-ART drugs - Mark Mascolini (05/28/18)   CSF is not on-target marker of antiretroviral and fluconazole levels in brain - Mark Mascolini (05/28/18)   No oral cabotegravir dose adjustment expected with rifabutin - Mark Mascolini (05/28/18)   Comparison of Relative Bioavailability of TIVICAY Immediate Release and Dispersible Pediatric Tablets to Immediate Release TIVICAY Adult Tablets - (05/28/18)   Pharmacokinetics, Metabolism and Excretion of Radiolabeled Fostemsavir Administered With or Without Ritonavir in Healthy Male Subjects - (05/28/18)   Rifabutin (RBT) Decreases Cabotegravir (CAB) Exposure Following Oral Co-administration - (05/28/18)   Assessment of maternal and fetal dolutegravir exposure by integrating ex vivoplacental perfusion data and physiologically-based pharmacokinetic modeling - (05/28/18)   Pharmacokinetic and virological efficacy of dolutegravir (50 mg BID) containing regimen in association with rifampin in HIV-infected patients using Dried Blood Spot: ANRS-12313 NAMSAL sub-study in Cameroon - (05/28/18)   Bictegravir/Emtricitabine/Tenofovir Alafenamide Phase 3 Exposure-Response Analysis of Safety and Efficacy in the Treatment of HIV Infection - (05/28/18)   PHARMACOKINETICS OF DOLUTEGRAVIR 100 MG ONCE-DAILY WITH RIFAMPICIN - (05/26/18)   Elvitegravir pharmacokinetics during Pregnancy and Postpartum - (05/26/18)   First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women - (05/26/18)   Glecaprevir/pibrentasvir SVR12 at 97% regardless of psychiatric disorders - Mark Mascolini - (05/25/18)   Elvitegravir pharmacokinetics during pregnancy and postpartum Low elvitegravir troughs in third trimester confirm caution in pregnancy - Mark Mascolini - (05/25/18)   First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women - Unbound dolutegravir trough similar in third trimester and postpartum - Mark Mascolini - (05/25/18)   Elvitegravir pharmacokinetics during pregnancy and postpartum Low elvitegravir troughs in third trimester confirm caution in pregnancy - Mark Mascolini - (05/25/18)   Does hepatic impairment affect the exposure of monoclonal antibodies? - Mark Mascolini - (05/25/18)   Intracellular 007-TP Concentrations are Associated with Gradients of Adherence to Ledipasvir/Sofosbuvir - (05/25/18)   Differing drug distribution in penis and rectum of men taking TDF/FTC PrEP - Mark Mascolini - (05/25/18)   Adherence gradient strongly tied to sofosbuvir triphosphate level in HCV/HIV group - Mark Mascolini - (05/25/18)